Rates of Liver Cancers Are Going Up – and Communities of Color Face the Most Risk

Rates of Liver Cancers Are Going Up – and Communities of Color Face the Most Risk

Untitled (1600 × 500 Px)

Rates of Liver Cancers Are Going Up – and Communities of Color Face the Most Risk

Global Liver Institute Launches 5th Annual #OctoberIs4Livers Campaign: Driving Equity in Liver Cancers

Washington, DC – October 1, 2022 – Global Liver Institute (GLI) today launches its 5th annual #OctoberIs4Liver education and awareness campaign, which calls attention to liver cancer – the third deadliest cancer in the world. Throughout the month, GLI will use media, social media, educational expert panels, and other events to bring patients, survivors, caregivers, advocates, clinical experts, industry, and policymakers together around this critical issue.

A liver cancer diagnosis provides a bleak outlook for over 900,000 people around the world each year. Five years after being diagnosed, less than a third of people are still alive. In South Korea, which has the best outcomes, just under 33% of people survive this long; in the U.S., for instance, only 20% do. Tragically, around 70% of these cases of liver cancer could have been prevented by eliminating many modifiable risk factors. This fact makes it more troubling that vulnerable populations, especially indigineous and ethnic minority communities around the world, bear a greater burden of liver cancers than majority populations. In the U.S., for example, Asian American men are 70% more likely than non-Hispanic white men to develop liver cancer. Similar inequity is evident across many demographic categories.

“Liver cancer is a grim disease, and it poses a formidable challenge to the world. That is why it is so essential that we join as a global community to stop upstream risk factors, improve access to care, and create new methods for treatment,” shared Sarah Manes, Director of Liver Cancers Programs at GLI. “We feel privileged at GLI to join with leaders across expertises and geographies to dive into candid conversation and to strengthen relationships. As GLI connects research, clinical, patient, and policy leaders, we will bring the daunting, nuanced challenges of this disease to the most brilliant minds in the field.”

There is something to look forward to all month! 

    • Weekly Health Equity Roundtable conversations with leaders to discuss the unique challenges of liver cancer to LatinX, Black, Asian American, and LGBTQ+ people
    • The second annual Leadership in Liver Health Luncheon, during which GLI will honor trailblazers in health.
    • Several patient highlights to elevate the stories of liver cancer survivors
    • Episodes of GLI LIVE each Wednesday at noon ET to discuss the innovators changing the game for liver cancer care and prevention
    • Updates to The State of Liver Cancer Report, the Global Liver Cancers Map
    • The release of Liver Cancer Lessons education resources and videos in French, Spanish, and Mandarin on livercentral.org
    • The global premier of Fighting Liver Cancers with Food, GLI’s 3-part cooking show featuring celebrity Chef Daniel Thomas:
      • Eating for Energy
      • Eating for Comfort
      • Eating for Strength
    • And more!

Jpeg Artboard 1

“The #OctoberIs4Livers campaign, now in its fifth year, embodies the mission of GLI to improve the lives of patients by promoting the innovation and collaboration that will one day eradicate liver cancers. Despite the growing impact of liver cancer that encumbers our world, the disease receives insufficient funding and focus relative to the need,” GLI’s President and CEO, Donna R. Cryer, JD, said. “In alignment with President Biden’s recent remarks on the Cancer Moonshot Initiative, it is indeed time to reimagine the possibilities for prevention and treatment of liver cancers. The hundreds of thousands of people who are going to hear the words ‘you have liver cancer’ this year rely on innovation – in diagnostics, in navigation, and in policies – to save them.”

In addition to GLI’s events, our partners (including GLI’s Liver Action Network members and members of the Liver Cancers Council) will also be hosting webinars, fireside chats, and liver cancer care center open houses throughout the month.

Please join us the #OctoberIs4Livers Campaign! 

  1. Register to attend the weekly Health Equity Roundtables.
  2. Use our social media toolkit to share ready-to-use messages with your friends, family, and followers.
  3. Join the conversation on social media with #OctoberIs4Livers.
  4. Sign our pledge to double the survival rate for liver cancer in your country by 2030.
  5. Mark your calendar for GLI LIVE, which airs weekly at 12PM ET on Facebook, Twitter, and YouTube.


About Global Liver Institute

Global Liver Institute (GLI) is a 501(c)3 nonprofit organization founded in the belief that liver health must take its place on the global public health agenda commensurate with the prevalence and impact of liver illness. GLI promotes innovation, encourages collaboration, and supports the scaling of optimal approaches to help eradicate liver diseases. Operating globally, GLI is committed to solving the problems that matter to liver patients and equipping advocates to improve the lives of individuals and families impacted by liver disease. Follow GLI on Twitter, Facebook, Instagram, LinkedIn, and YouTube.


Liver Cancer Won’t Wait. We Shouldn’t Either.

Liver Cancer Won’t Wait. We Shouldn’t Either.

Liver Cancer Banner 01

“You have liver cancer.” It’s a sentence that nobody wants to hear, but far too many people have heard (likely hundreds of thousands this year). Despite the prominent position that cancer has played in the public consciousness over the past 50 years, liver cancer – one of the deadliest cancers, one that is becoming more common – still hardly creates an echo.

We’re committed to changing that. Welcome to the very first edition of Liver Cancer News. As we expand our offerings for and about the broader liver health community, Global Liver Institute remains committed to keeping you informed about liver cancer. Each edition will include upcoming events, patient stories, exciting news, and more.

The tragedy of liver cancer is extended by the fact that in the vast majority of cases (at least 70%), the disease could have been prevented. It is sadly no surprise that a disproportionate brunt of this burden is born by vulnerable communities – the racial, ethnic, and sexual minorities who face barriers to health education, care, and more. To achieve the goals of the re-ignited Cancer Moonshot, it’s imperative to address liver cancer – and so, to address the needs of these vulnerable groups. Collectively, we have the tools to make a huge difference in the incidence of liver cancer. It’s time to use them.

OctoberIs4LiversThus, the theme for GLI’s
#OctoberIs4Livers campaign this year –  Driving Equity in Liver Cancers – highlights an absolutely essential need. We are proud to launch the 5th annual iteration of the first and only global campaign dedicated to public awareness, policy, and clinical practice needs to prevent and manage liver cancer while educating and empowering those impacted by it. This year, we will connect diverse communities around the world – from our home in Washington D.C. to yours – to highlight, fight, and reduce the disparities associated with this cancer that has continued to rise for decades. 

Advancing liver health equity takes collective effort. From doctors to scientists and from patients to caregivers, you are important in moving the needle forward. Start by signing GLI’s Global Call to Action, which aims to double the five-year survival rate for liver cancers by 2030. We hope you will join us by signing this pledge, and also hope you will join the conversation throughout #OctoberIs4Liver. We can’t afford to wait.

DRC Signature

Donna R. Cryer, JD
President & CEO
Global Liver Institute



Jpeg Artboard 1

GLI is proud to release our 2022 #OctoberIs4Livers event calendar!

Every week during October, GLI will be broadcasting GLI LIVE episodes and Health Equity Roundtables for Black, LatinX/Hispanic, Asian and Asian American, and LGBTQ+ communities.

These Roundtables will launch ongoing Health Equity Community Conversations, starting in 2023! In addition to weekly sessions on timely topics in equity and innovation, keep an eye out for:

    • Liver Cancer Lessons in new languages
    • Social Media Toolkit so you can get involved
    • Fighting Liver Cancers with Food, a 3-part cooking show
    • New resources evaluating barriers to success in combating liver cancer in regions around the world
    • Liver cancer center open houses around the world
    • More events from our friends & partners

    Learn more!

    Upcoming Initiatives & Events

    Leadership In Liver Health Luncheon

    October 17, 2022: Leadership in Liver Health Luncheon

    Join us this year as we honor the Leadership in Liver Health Award recipients: 

    • Dr. Michelle McMurry-Heath, President and CEO of Biotechnology Innovation Organization
    • Dr. Leana S. Wen, Public Health Professor, George Washington University and Contributing Columnist, Washington Post

    Email dthomas@globalliver.org for sponsorship opportunities or more information on attending.

    TLM2022 HeaderLogoNovember 4-8, 2022 : GLI at AASLD’s The Liver Meeting

    Global Liver Institute will be at AASLD in Washington, D.C., in November! Swing by to say hello at booth #237 or email info@globalliver.org to set up a meeting with us.

    Patient Perspectives

    Cholangiocarcinoma FoundationPatient Name: Melinda Bachini

    City/State/Country: Billings, MT, USA

    Disease(s): Bile Duct/Liver Cancer (2009 – Present)

    After brushing off the symptoms of shoulder pain, fatigue, and GI issues as part of my career as a paramedic, I eventually scheduled an appointment with my primary care physician in 2009. An ultrasound revealed that I had a grapefruit-sized tumor on my liver. The liver resection, which removed two-thirds of my liver, confirmed that I had intrahepatic cholangiocarcinoma. Three months after the resection, my cancer came back, and I knew the only way to beat it was by participating in a clinical trial, which I credit the persistence of my oncologist for finding. Read the full story

    Anthony Villiotti HeadshotPatient Name: Anthony Villiotti

    City/State/Country: Springfield, Illinois, USA

    Disease(s): Type II Diabetes (1985 – Present); NASH (2014 – 2018); Cirrhosis (2015-2018); Liver Cancer (2017 – 2018)

    A transplant can be a lifesaver, but it is not a get out of jail free card; after all, it carries ramifications that highlight the importance of early diagnosis and prevention as you are much better off not having to go through this obstacle in life. Unfortunately, early diagnosis and prevention is hampered by a lack of awareness around liver health. We grow up not knowing much about our liver. This further drives the stigma against having liver cancer. When my wife shared my liver cancer diagnosis with others, people often made assumptions about my alcohol consumption patterns. Read the full story

    Share your story with us!

    GLI Partner Highlights


    From June 3-7, 2022, 40,000 oncology professionals joined together at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. GLI attended to hear the latest clinical cancer advances in all areas of cancer research.



    The first Africa HepatoPancreatoBiliary Cancer Consortium Conference was held in Cairo, Egypt on August 28, 2022. GLI provided welcoming remarks.

    Sarah TeCH 1GLI was invited to be a part of the Multi-stakeholder Texas Collaborative Center for Hepatocellular Cancer (TeCH) meeting on September 17, 2022. This conference brought together elected officials and decision-makers, community groups, and industry partners to discuss HCC in Texas and how we might guide strategies to improve HCC prevention, screening, diagnosis, and treatment.

    Research & Development

    On September 2, 2022, AstraZeneca, one of GLIs Liver Cancer Council corporate members, received FDA approval for durvalumab (Imfinzi, AstraZeneca UK Limited) in combination with gemcitabine and cisplatin for adult patients with locally advanced or metastatic biliary tract cancer (BTC). Congratulations to everyone involved in bringing this first immunotherapy treatment to patients with this rare, aggressive cancer.

    Liver Cancer Won’t Wait. We Shouldn’t Either.

    Global Liver Institute Congratulates Dr. Monica Bertagnolli for Imminent Appointment as Director of the National Cancer Institute

    Washington, DC – August 12, 2022 –  As leaders in the liver cancers community, Global Liver Institute (GLI) proudly supports President Biden’s selection of Monica Bertagnolli, MD, to be appointed as the Director of the National Cancer Institute (NCI).

    Bertagnolli is the first woman to serve as chief of the Division of Surgical Oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute and is a professor of surgery at Harvard Medical School. She was recently elected to the National Academy of Medicine and served as the president of the American Society of Clinical Oncology.

    “Global Liver Institute and our liver cancers team are grateful for President Biden appointing Dr. Monica Bertagnolli to be the first woman to serve as Director of the National Cancer Institute,” said Sarah Manes, Liver Cancers Program Director at GLI. “Dr. Bertagnolli’s esteemed and extensive clinical oncology experience, health policy work, and clinical trial expertise will continue to drive NCI to lead in the space of cancer research and innovation.”

    Liver cancer presents a sizable burden as the sixth most common cancer and third leading cause of worldwide cancer death. Further, liver cancer is one of the few cancers that is on the rise – its incidence is expected to grow 137% by 2030. GLI remains committed to being an ally and driving focus on liver cancers advocacy specifically for hepatobiliary NCI SPORE grants and state-and-global-specific cancer consortiums. We look forward to collaborating with Dr. Monica Bertagnolli and the NCI on Cancer Moonshot initiatives as we persist in our efforts to drive policy, education, and awareness of liver disease and liver cancers by increasing screening, treatment, and prevention of one of the deadliest cancers in the world. We are also thankful to Dr. Douglas Lowy, MD, for serving as NCI’s acting director upon the departure of Ned Sharpless, MD.